v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table reconciles reported revenues to net loss under the significant expense principle for the three and six months ended June 30, 2026 and 2025:
Three Months Ended June 30,Six Months Ended
June 30,
2026202520262025
Revenues$13,819 $10,003 $28,265 $18,723 
Costs and expenses:
Total Manufacture and Supply Expenses
4,017 4,561 7,486 8,213 
R&D Project expenses:
Anaphylm project expenses
1,055 1,204 2,140 3,692 
AQST-108 project expenses152 190 710 385 
R&D other expenses:
Personnel costs1
2,181 2,218 4,423 4,350 
Other2
574 493 893 1,039 
Total Research and Development Expenses
3,962 4,105 8,166 9,466 
Selling expenses:
Personnel costs3
1,730 608 3,374 1,302 
Other4
444 2,912 721 5,174 
Total Selling expenses
2,174 3,520 4,095 6,476 
General & Administrative expenses:
Personnel costs5
6,602 5,176 12,111 10,016 
Other6
5,287 4,009 8,834 15,285 
Total General and Administrative Expenses
11,889 9,185 20,945 25,301 
Total Selling, General and Administrative Expenses
14,063 12,705 25,040 31,777 
Total costs and expenses22,042 21,371 40,692 49,456 
Loss from operations(8,223)(11,368)(12,427)(30,733)
Other income/(expenses), net
(14,641)(2,180)(18,494)(5,745)
Net loss before income taxes(22,864)(13,548)(30,921)(36,478)
Net loss$(22,864)$(13,548)$(30,921)$(36,478)
Comprehensive loss$(22,864)$(13,548)$(30,921)$(36,478)
1 - R&D Personnel costs include payroll expenses, share-based compensation expenses and severance
2 - Other R&D expenses include preclinical, consulting, maintenance, and testing fees
3 - Selling Personnel costs include payroll expenses, share-based compensation expenses and severance
4 - Other Selling expenses include commercialization and other related expenses
5 - G&A Personnel costs include payroll expenses, share-based compensation expenses and severance
6 - Other General and Administrative expenses include legal/patent fees, insurance fees, IT expenses, investor relations expenses, regulatory fees, facility and other costs